Theracosbio Drug Patent Portfolio
Theracosbio owns 1 orange book drug protected by 6 US patents Given below is the list of Theracosbio's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8987323 | Crystalline form of benzylbenzene SGLT2 inhibitor | 14 May, 2032 | Active |
| US10533032 | Crystalline form of benzylbenzene SGLT2 inhibitor | 03 Jul, 2031 | Active |
| US10981942 | Crystalline form of benzylbenzene SGLT2 inhibitor | 13 Jun, 2031 | Active |
| US7838499 | Benzylbenzene derivatives and methods of use | 30 Jan, 2029 | Active |
| US8106021 | Benzylbenzene derivatives and methods of use | 22 Aug, 2028 | Active |
| US8802637 | Benzylbenzene derivatives and methods of use | 22 Aug, 2028 | Active |
Latest Legal Activities on Theracosbio's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Theracosbio.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 26 Aug, 2025 | US8802637 |
| Second letter to regulating agency to determine regulatory review period | 26 Aug, 2025 | US8106021 |
| transaction for FDA Determination of Regulatory Review Period | 26 Aug, 2025 | US7838499 |
| transaction for FDA Determination of Regulatory Review Period | 26 Aug, 2025 | US10533032 |
| Information Disclosure Statement (IDS) Filed | 26 Aug, 2025 | US10533032 |
| transaction for FDA Determination of Regulatory Review Period | 26 Aug, 2025 | US10981942 |
| Second letter to regulating agency to determine regulatory review period | 21 Aug, 2025 | US8987323 |
| Letter from FDA or Dept of Agriculture re PTE application | 19 Aug, 2025 | US8987323 |
| Letter from FDA or Dept of Agriculture re PTE application | 19 Aug, 2025 | US8106021 |
| Change in Power of Attorney (May Include Associate POA) | 11 Jul, 2025 | US10533032 |
| Email Notification | 11 Jul, 2025 | US10533032 |
| Second letter to regulating agency to determine regulatory review period | 10 Jul, 2025 | US7838499 |
| Second letter to regulating agency to determine regulatory review period | 10 Jul, 2025 | US8802637 |
| Second letter to regulating agency to determine regulatory review period | 10 Jul, 2025 | US10533032 |
| Second letter to regulating agency to determine regulatory review period | 10 Jul, 2025 | US10981942 |
Theracosbio's Family Patents
Theracosbio Drug List
Given below is the complete list of Theracosbio's drugs and the patents protecting them.
1. Brenzavvy
Brenzavvy is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8987323 | Crystalline form of benzylbenzene SGLT2 inhibitor |
14 May, 2032
(6 years from now)
| Active |
| US10533032 | Crystalline form of benzylbenzene SGLT2 inhibitor |
03 Jul, 2031
(5 years from now)
| Active |
| US10981942 | Crystalline form of benzylbenzene SGLT2 inhibitor |
13 Jun, 2031
(5 years from now)
| Active |
| US7838499 | Benzylbenzene derivatives and methods of use |
30 Jan, 2029
(2 years from now)
| Active |
| US8106021 | Benzylbenzene derivatives and methods of use |
22 Aug, 2028
(2 years from now)
| Active |
| US8802637 | Benzylbenzene derivatives and methods of use |
22 Aug, 2028
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Brenzavvy's drug page